Home Newsfeeds UPDATE: Kala Pharmaceuticals Q4 Adj. EPS $(6.46) Up From $(33.94) YoY

UPDATE: Kala Pharmaceuticals Q4 Adj. EPS $(6.46) Up From $(33.94) YoY

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(6.46) per share. This is a 80.97 percent increase over losses of $(33.94) per share from the same period last year.

byHappy Mohamed

March 3, 2023

1 minute read

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(6.46) per share. This is a 80.97 percent increase over losses of $(33.94) per share from the same period last year.

Baird Maintains Outperform on Cintas, Raises Price Target to $475

By Benzinga Newsdesk

August 17, 8:07 AM

Baird analyst Andrew Wittmann maintains Cintas (NASDAQ:CTAS) with a Outperform and raises the price target from $440 to $475.

CTAS

Twitter Whistleblower Opens New Can Of Worms: A Chinese Spy On Company’s Payroll?

By Shivdeep Dhaliwal

September 14, 12:28 AM

The testimony of Peiter Zatko, a Twitter Inc (NYSE: TWTR) whistleblower, before the Senate on Tuesday highlighted fears of the presence of a Chinese agent on the payrolls of the platform.

TSLA

Norwegian Cruise Line Sets Sail With Elon Musk’s Starlink: High-Speed Internet For Passengers

By Shivani Kumaresan

April 6, 11:50 AM

Global cruise company Norwegian Cruise Line Holdings Ltd (NYSE:NCLH) will offer SpaceX’s Starlink high-speed internet on its ships. Starlink’s connectivity will…

NCLH